Skip to main content
Top
Published in: Critical Care 6/2014

Open Access 01-12-2014 | Research

Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds

Authors: Andrew A Udy, Paul Jarrett, Janine Stuart, Melissa Lassig-Smith, Therese Starr, Rachel Dunlop, Steven C Wallis, Jason A Roberts, Jeffrey Lipman

Published in: Critical Care | Issue 6/2014

Login to get access

Abstract

Introduction

The aim of this study was to explore changes in glomerular filtration (GFR) and renal tubular function in critically ill patients at risk of augmented renal clearance (ARC), using exogenous marker compounds.

Methods

This prospective, observational pharmacokinetic (PK) study was performed in a university-affiliated, tertiary-level, adult intensive care unit (ICU). Patients aged less than or equal to 60 years, manifesting a systemic inflammatory response, with an expected ICU length of stay more than 24 hours, no evidence of acute renal impairment (plasma creatinine concentration <120 μmol/L) and no history of chronic kidney disease or renal replacement therapy were eligible for inclusion. The following study markers were administered concurrently: sinistrin 2,500 mg (Inutest; Laevosan, Linz, Austria), p-aminohippuric acid (PAH) 440 mg (4% p-aminohippuric acid sodium salt; CFM Oskar Tropitzsch, Marktredwitz, Germany), rac-pindolol 5 or 15 mg (Barbloc; Alphapharm, Millers Point, NSW, Australia) and fluconazole 100 mg (Diflucan; Pfizer Australia Pty Ltd, West Ryde, NSW, Australia). Plasma concentrations were then measured at 5, 10, 15, 30, 60 and 120 minutes and 4, 6, 12 and 24 hours post-administration. Non-compartmental PK analysis was used to quantify GFR, tubular secretion and tubular reabsorption.

Results

Twenty patients were included in the study. Marker administration was well tolerated, with no adverse events reported. Sinistrin clearance as a marker of GFR was significantly elevated (mean, 180 (95% confidence interval (CI), 141 to 219) ml/min) and correlated well with creatinine clearance (r =0.70, P <0.01). Net tubular secretion of PAH, a marker of tubular anion secretion, was also elevated (mean, 428 (95% CI, 306 to 550) ml/min), as was net tubular reabsorption of fluconazole (mean, 135 (95% CI, 100 to 169) ml/min). Net tubular secretion of (S)- and (R)-pinodolol, a marker of tubular cation secretion, was impaired.

Conclusions

In critically ill patients at risk of ARC, significant alterations in glomerular filtration, renal tubular secretion and tubular reabsorption are apparent. This has implications for accurate dosing of renally eliminated drugs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J: Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010, 49: 1-16. 10.2165/11318140-000000000-00000.CrossRef Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J: Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010, 49: 1-16. 10.2165/11318140-000000000-00000.CrossRef
2.
go back to reference Conil JM, Georges B, Mimoz O, Dieye E, Ruiz S, Cougot P, Samii K, Houin G, Saivin S: Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Intensive Care Med. 2006, 32: 2063-2066. 10.1007/s00134-006-0421-1.CrossRef Conil JM, Georges B, Mimoz O, Dieye E, Ruiz S, Cougot P, Samii K, Houin G, Saivin S: Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Intensive Care Med. 2006, 32: 2063-2066. 10.1007/s00134-006-0421-1.CrossRef
3.
go back to reference Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA: Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012, 142: 30-39. 10.1378/chest.11-1671.CrossRef Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA: Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012, 142: 30-39. 10.1378/chest.11-1671.CrossRef
4.
go back to reference Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ: Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care. 2013, 28: 695-700. 10.1016/j.jcrc.2013.03.003.CrossRef Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ: Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care. 2013, 28: 695-700. 10.1016/j.jcrc.2013.03.003.CrossRef
5.
go back to reference Baptista JP, Sousa E, Martins PJ, Pimentel JM: Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents. 2012, 39: 420-423. 10.1016/j.ijantimicag.2011.12.011.CrossRef Baptista JP, Sousa E, Martins PJ, Pimentel JM: Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents. 2012, 39: 420-423. 10.1016/j.ijantimicag.2011.12.011.CrossRef
6.
go back to reference Udy A, Roberts JA, Boots RJ, Lipman J: You only find what you look for: the importance of high creatinine clearance in the critically ill. Anaesth Intensive Care. 2009, 37: 11-13. Udy A, Roberts JA, Boots RJ, Lipman J: You only find what you look for: the importance of high creatinine clearance in the critically ill. Anaesth Intensive Care. 2009, 37: 11-13.
7.
go back to reference Lipman J, Udy AA, Roberts JA: Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story. Anaesth Intensive Care. 2011, 39: 999-1000. Lipman J, Udy AA, Roberts JA: Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story. Anaesth Intensive Care. 2011, 39: 999-1000.
8.
go back to reference Tett SE, Kirkpatrick CM, Gross AS, McLachlan AJ: Principles and clinical application of assessing alterations in renal elimination pathways. Clin Pharmacokinet. 2003, 42: 1193-1211. 10.2165/00003088-200342140-00002.CrossRef Tett SE, Kirkpatrick CM, Gross AS, McLachlan AJ: Principles and clinical application of assessing alterations in renal elimination pathways. Clin Pharmacokinet. 2003, 42: 1193-1211. 10.2165/00003088-200342140-00002.CrossRef
9.
go back to reference Gross AS, McLachlan AJ, Minns I, Beal JB, Tett SE: Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. Br J Clin Pharmacol. 2001, 51: 547-555. 10.1046/j.1365-2125.2001.01390.x.CrossRef Gross AS, McLachlan AJ, Minns I, Beal JB, Tett SE: Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. Br J Clin Pharmacol. 2001, 51: 547-555. 10.1046/j.1365-2125.2001.01390.x.CrossRef
10.
go back to reference Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992, 101: 1644-1655. 10.1378/chest.101.6.1644.CrossRef Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992, 101: 1644-1655. 10.1378/chest.101.6.1644.CrossRef
11.
go back to reference Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, cute Dialysis Quality Initiative: AAcute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004, 8: R204-R212. 10.1186/cc2872.CrossRef Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, cute Dialysis Quality Initiative: AAcute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004, 8: R204-R212. 10.1186/cc2872.CrossRef
12.
go back to reference Johnson DW, Jones GR, Mathew TH, Ludlow MJ, Doogue MP, Jose MD, Langham RG, Lawton PD, McTaggart SJ, Peake MJ, Polkinghorne K, Usherwood T: Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust. 2012, 197: 224-225. Johnson DW, Jones GR, Mathew TH, Ludlow MJ, Doogue MP, Jose MD, Langham RG, Lawton PD, McTaggart SJ, Peake MJ, Polkinghorne K, Usherwood T: Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust. 2012, 197: 224-225.
13.
go back to reference Buclin T, Pechère-Bertschi A, Séchaud R, Décosterd LA, Munafo A, Burnier M, Biollaz J: Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method. J Clin Pharmacol. 1997, 37: 679-692. 10.1002/j.1552-4604.1997.tb04355.x.CrossRef Buclin T, Pechère-Bertschi A, Séchaud R, Décosterd LA, Munafo A, Burnier M, Biollaz J: Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method. J Clin Pharmacol. 1997, 37: 679-692. 10.1002/j.1552-4604.1997.tb04355.x.CrossRef
14.
go back to reference Hsyu PH, Giacomini KM: Stereoselective renal clearance of pindolol in humans. J Clin Invest. 1985, 76: 1720-1726. 10.1172/JCI112161.CrossRef Hsyu PH, Giacomini KM: Stereoselective renal clearance of pindolol in humans. J Clin Invest. 1985, 76: 1720-1726. 10.1172/JCI112161.CrossRef
15.
go back to reference Carlier M, Carrette S, Roberts JA, Stove V, Verstraete AG, Hoste E, Decruyenaere J, Depuydt P, Lipman J, Wallis SC, De Waele JJ: Meropenem and piperacillin/tazobactam prescribing in critically ill patients: Does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?. Crit Care. 2013, 17: R84-10.1186/cc12705.CrossRef Carlier M, Carrette S, Roberts JA, Stove V, Verstraete AG, Hoste E, Decruyenaere J, Depuydt P, Lipman J, Wallis SC, De Waele JJ: Meropenem and piperacillin/tazobactam prescribing in critically ill patients: Does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?. Crit Care. 2013, 17: R84-10.1186/cc12705.CrossRef
16.
go back to reference Buclin T, Sechaud R, Bertschi AP, Decosterd LA, Belaz N, Appenzeller M, Burnier M, Biollaz J: Estimation of glomerular filtration rate by sinistrin clearance using various approaches. Ren Fail. 1998, 20: 267-276. 10.3109/08860229809045111.CrossRef Buclin T, Sechaud R, Bertschi AP, Decosterd LA, Belaz N, Appenzeller M, Burnier M, Biollaz J: Estimation of glomerular filtration rate by sinistrin clearance using various approaches. Ren Fail. 1998, 20: 267-276. 10.3109/08860229809045111.CrossRef
17.
go back to reference Estelberger W, Petek W, Zitta S, Mauric A, Horn S, Holzer H, Pogglitsch H: Determination of the glomerular filtration rate by identification of sinistrin kinetics. Eur J Clin Chem Clin Biochem. 1995, 33: 201-209. Estelberger W, Petek W, Zitta S, Mauric A, Horn S, Holzer H, Pogglitsch H: Determination of the glomerular filtration rate by identification of sinistrin kinetics. Eur J Clin Chem Clin Biochem. 1995, 33: 201-209.
18.
go back to reference Prescott LF, Freestone S, McAuslane JA: The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function. Br J Clin Pharmacol. 1993, 35: 20-29. Prescott LF, Freestone S, McAuslane JA: The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function. Br J Clin Pharmacol. 1993, 35: 20-29.
19.
go back to reference Dowling TC, Frye RF, Fraley DS, Matzke GR: Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. Kidney Int. 2001, 59: 295-303. 10.1046/j.1523-1755.2001.00491.x.CrossRef Dowling TC, Frye RF, Fraley DS, Matzke GR: Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. Kidney Int. 2001, 59: 295-303. 10.1046/j.1523-1755.2001.00491.x.CrossRef
20.
go back to reference Cole BR, Giangiacomo J, Ingelfinger JR, Robson AM: Measurement of renal function without urine collection—a critical evaluation of the constant-infusion technic for determination of inulin and para-aminohippurate. N Engl J Med. 1972, 287: 1109-1114. 10.1056/NEJM197211302872202.CrossRef Cole BR, Giangiacomo J, Ingelfinger JR, Robson AM: Measurement of renal function without urine collection—a critical evaluation of the constant-infusion technic for determination of inulin and para-aminohippurate. N Engl J Med. 1972, 287: 1109-1114. 10.1056/NEJM197211302872202.CrossRef
21.
go back to reference Sinnollareddy M, Peake SL, Roberts MS, Playford EG, Lipman J, Roberts JA: Pharmacokinetic evaluation of fluconazole in critically ill patients. Expert Opin Drug Metab Toxicol. 2011, 7: 1431-1440. 10.1517/17425255.2011.615309.CrossRef Sinnollareddy M, Peake SL, Roberts MS, Playford EG, Lipman J, Roberts JA: Pharmacokinetic evaluation of fluconazole in critically ill patients. Expert Opin Drug Metab Toxicol. 2011, 7: 1431-1440. 10.1517/17425255.2011.615309.CrossRef
22.
go back to reference Toon S, Ross CE, Gokal R, Rowland M: An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol. 1990, 29: 221-226. 10.1111/j.1365-2125.1990.tb03623.x.CrossRef Toon S, Ross CE, Gokal R, Rowland M: An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol. 1990, 29: 221-226. 10.1111/j.1365-2125.1990.tb03623.x.CrossRef
23.
go back to reference Ujhelyi MR, Bottorff MB, Schur M, Roll K, Zhang H, Stewart J, Markel ML: Urine acidification affects the activity of the organic base transporter in a nonstereoselective manner. J Pharmacol Exp Ther. 1996, 276: 683-689. Ujhelyi MR, Bottorff MB, Schur M, Roll K, Zhang H, Stewart J, Markel ML: Urine acidification affects the activity of the organic base transporter in a nonstereoselective manner. J Pharmacol Exp Ther. 1996, 276: 683-689.
24.
go back to reference Somogyi AA, Bochner F, Sallustio BC: Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther. 1992, 51: 379-387. 10.1038/clpt.1992.37.CrossRef Somogyi AA, Bochner F, Sallustio BC: Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther. 1992, 51: 379-387. 10.1038/clpt.1992.37.CrossRef
25.
go back to reference Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, Sugiyama Y: Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 2012, 340: 393-403. 10.1124/jpet.111.184986.CrossRef Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, Sugiyama Y: Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 2012, 340: 393-403. 10.1124/jpet.111.184986.CrossRef
26.
go back to reference Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM: Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem. 2013, 56: 781-795. 10.1021/jm301302s.CrossRef Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM: Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem. 2013, 56: 781-795. 10.1021/jm301302s.CrossRef
27.
go back to reference McLachlan AJ, Gross AS, Beal JL, Minns I, Tett SE: Analytical validation for a series of marker compounds used to assess renal drug elimination processes. Ther Drug Monit. 2001, 23: 39-46. 10.1097/00007691-200102000-00008.CrossRef McLachlan AJ, Gross AS, Beal JL, Minns I, Tett SE: Analytical validation for a series of marker compounds used to assess renal drug elimination processes. Ther Drug Monit. 2001, 23: 39-46. 10.1097/00007691-200102000-00008.CrossRef
28.
go back to reference Wainer E, Boner G, Rosenfeld JB: Effects of pindolol on renal function. Clin Pharmacol Ther. 1980, 28: 575-580. 10.1038/clpt.1980.205.CrossRef Wainer E, Boner G, Rosenfeld JB: Effects of pindolol on renal function. Clin Pharmacol Ther. 1980, 28: 575-580. 10.1038/clpt.1980.205.CrossRef
29.
go back to reference Lee LJ, Smith DE: Renal excretion and metabolism of p-aminohippurate in the isolated perfused rat kidney. Pharm Res. 1988, 5: 745-747. 10.1023/A:1015924331585.CrossRef Lee LJ, Smith DE: Renal excretion and metabolism of p-aminohippurate in the isolated perfused rat kidney. Pharm Res. 1988, 5: 745-747. 10.1023/A:1015924331585.CrossRef
30.
go back to reference Buijk SL, Gyssens IC, Mouton JW, Verbrugh HA, Touw DJ, Bruining HA: Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med. 2001, 27: 115-121. 10.1007/s001340000771.CrossRef Buijk SL, Gyssens IC, Mouton JW, Verbrugh HA, Touw DJ, Bruining HA: Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med. 2001, 27: 115-121. 10.1007/s001340000771.CrossRef
31.
go back to reference Udy A, Boots R, Senthuran S, Stuart J, Deans R, Lassig-Smith M, Lipman J: Augmented creatinine clearance in traumatic brain injury. Anesth Analg. 2010, 111: 1505-1510. 10.1213/ANE.0b013e3181f7107d.CrossRef Udy A, Boots R, Senthuran S, Stuart J, Deans R, Lassig-Smith M, Lipman J: Augmented creatinine clearance in traumatic brain injury. Anesth Analg. 2010, 111: 1505-1510. 10.1213/ANE.0b013e3181f7107d.CrossRef
32.
go back to reference Udy AA, Baptista JP, Lim NL, Joynt GM, Jarrett P, Wockner L, Boots RJ, Lipman J: Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically Ill patients with normal plasma creatinine concentrations. Crit Care Med. 2014, 42: 520-527. 10.1097/CCM.0000000000000029.CrossRef Udy AA, Baptista JP, Lim NL, Joynt GM, Jarrett P, Wockner L, Boots RJ, Lipman J: Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically Ill patients with normal plasma creatinine concentrations. Crit Care Med. 2014, 42: 520-527. 10.1097/CCM.0000000000000029.CrossRef
33.
go back to reference Minville V, Asehnoune K, Ruiz S, Breden A, Georges B, Seguin T, Tack I, Jaafar A, Saivin S, Fourcade O, Samii K, Conil JM: Increased creatinine clearance in polytrauma patients with normal serum creatinine: a retrospective observational study. Crit Care. 2011, 15: R49-10.1186/cc10013.CrossRef Minville V, Asehnoune K, Ruiz S, Breden A, Georges B, Seguin T, Tack I, Jaafar A, Saivin S, Fourcade O, Samii K, Conil JM: Increased creatinine clearance in polytrauma patients with normal serum creatinine: a retrospective observational study. Crit Care. 2011, 15: R49-10.1186/cc10013.CrossRef
34.
go back to reference Conil JM, Georges B, Fourcade O, Seguin T, Lavit M, Samii K, Houin G, Tack I, Saivin S: Assessment of renal function in clinical practice at the bedside of burn patients. Br J Clin Pharmacol. 2007, 63: 583-594. 10.1111/j.1365-2125.2006.02807.x.CrossRef Conil JM, Georges B, Fourcade O, Seguin T, Lavit M, Samii K, Houin G, Tack I, Saivin S: Assessment of renal function in clinical practice at the bedside of burn patients. Br J Clin Pharmacol. 2007, 63: 583-594. 10.1111/j.1365-2125.2006.02807.x.CrossRef
35.
go back to reference Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J: Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Crit Care. 2013, 17: R35-10.1186/cc12544.CrossRef Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J: Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Crit Care. 2013, 17: R35-10.1186/cc12544.CrossRef
36.
go back to reference Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL: Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: Look before you leap!. Clin Infect Dis. 2010, 51: S103-S110. 10.1086/653057.CrossRef Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL: Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: Look before you leap!. Clin Infect Dis. 2010, 51: S103-S110. 10.1086/653057.CrossRef
37.
go back to reference Lautrette A, Phan TN, Ouchchane L, Aithssain A, Tixier V, Heng AE, Souweine B: High creatinine clearance in critically ill patients with community-acquired acute infectious meningitis. BMC Nephrol. 2012, 13: 124-10.1186/1471-2369-13-124.CrossRef Lautrette A, Phan TN, Ouchchane L, Aithssain A, Tixier V, Heng AE, Souweine B: High creatinine clearance in critically ill patients with community-acquired acute infectious meningitis. BMC Nephrol. 2012, 13: 124-10.1186/1471-2369-13-124.CrossRef
38.
go back to reference Brown R, Babcock R, Talbert J, Gruenberg J, Czurak C, Campbell M: Renal function in critically ill postoperative patients: sequential assessment of creatinine osmolar and free water clearance. Crit Care Med. 1980, 8: 68-72. 10.1097/00003246-198002000-00004.CrossRef Brown R, Babcock R, Talbert J, Gruenberg J, Czurak C, Campbell M: Renal function in critically ill postoperative patients: sequential assessment of creatinine osmolar and free water clearance. Crit Care Med. 1980, 8: 68-72. 10.1097/00003246-198002000-00004.CrossRef
39.
go back to reference Fuster-Lluch O, Gerónimo-Pardo M, Peyró-García R, Lizán-García M: Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care. 2008, 36: 674-680. Fuster-Lluch O, Gerónimo-Pardo M, Peyró-García R, Lizán-García M: Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care. 2008, 36: 674-680.
40.
go back to reference Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D: Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med. 2013, 39: 1247-1252. 10.1007/s00134-013-2909-9.CrossRef Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D: Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med. 2013, 39: 1247-1252. 10.1007/s00134-013-2909-9.CrossRef
41.
go back to reference Thomas DM, Coles GA, Williams JD: What does the renal reserve mean?. Kidney Int. 1994, 45: 411-416. 10.1038/ki.1994.53.CrossRef Thomas DM, Coles GA, Williams JD: What does the renal reserve mean?. Kidney Int. 1994, 45: 411-416. 10.1038/ki.1994.53.CrossRef
42.
go back to reference Udy AA, Morton FJ, Nguyen-Pham S, Jarrett P, Lassig-Smith M, Stuart J, Dunlop R, Starr T, Boots RJ, Lipman J: A comparison of CKD-EPI estimated glomerular filtration rate and measured creatinine clearance in recently admitted critically ill patients with normal plasma creatinine concentrations. BMC Nephrol. 2013, 14: 250-10.1186/1471-2369-14-250.CrossRef Udy AA, Morton FJ, Nguyen-Pham S, Jarrett P, Lassig-Smith M, Stuart J, Dunlop R, Starr T, Boots RJ, Lipman J: A comparison of CKD-EPI estimated glomerular filtration rate and measured creatinine clearance in recently admitted critically ill patients with normal plasma creatinine concentrations. BMC Nephrol. 2013, 14: 250-10.1186/1471-2369-14-250.CrossRef
43.
go back to reference Bragadottir G, Redfors B, Ricksten SE: Assessing glomerular filtration rate (GFR) in critically ill patients with acute kidney injury - true GFR versus urinary creatinine clearance and estimating equations. Crit Care. 2013, 17: R108-10.1186/cc12777.CrossRef Bragadottir G, Redfors B, Ricksten SE: Assessing glomerular filtration rate (GFR) in critically ill patients with acute kidney injury - true GFR versus urinary creatinine clearance and estimating equations. Crit Care. 2013, 17: R108-10.1186/cc12777.CrossRef
44.
go back to reference Nicolau DP, Crowe H, Nightingale CH, Quintiliani R: Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother. 1995, 36: 395-401. 10.1093/jac/36.2.395.CrossRef Nicolau DP, Crowe H, Nightingale CH, Quintiliani R: Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother. 1995, 36: 395-401. 10.1093/jac/36.2.395.CrossRef
45.
go back to reference Meier J, Nuesch E: Pindolol, a β-adrenoceptor blocking agent with a negligible first-pass effect. Br J Clin Pharmacol. 1977, 4: 371-372. 10.1111/j.1365-2125.1977.tb00726.x.CrossRef Meier J, Nuesch E: Pindolol, a β-adrenoceptor blocking agent with a negligible first-pass effect. Br J Clin Pharmacol. 1977, 4: 371-372. 10.1111/j.1365-2125.1977.tb00726.x.CrossRef
46.
go back to reference Debruyne D: Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet. 1997, 33: 52-77. 10.2165/00003088-199733010-00005.CrossRef Debruyne D: Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet. 1997, 33: 52-77. 10.2165/00003088-199733010-00005.CrossRef
47.
go back to reference Hirata-Dulas CA, Awni WM, Matzke GR, Halstenson CE, Guay DR: Evaluation of two intravenous single-bolus methods for measuring effective renal plasma flow. Am J Kidney Dis. 1994, 23: 374-381. 10.1016/S0272-6386(12)80999-1.CrossRef Hirata-Dulas CA, Awni WM, Matzke GR, Halstenson CE, Guay DR: Evaluation of two intravenous single-bolus methods for measuring effective renal plasma flow. Am J Kidney Dis. 1994, 23: 374-381. 10.1016/S0272-6386(12)80999-1.CrossRef
Metadata
Title
Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds
Authors
Andrew A Udy
Paul Jarrett
Janine Stuart
Melissa Lassig-Smith
Therese Starr
Rachel Dunlop
Steven C Wallis
Jason A Roberts
Jeffrey Lipman
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 6/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-014-0657-z

Other articles of this Issue 6/2014

Critical Care 6/2014 Go to the issue